$5.45
+0.46 (+9.22%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ADIL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 2 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC) · FINRA short interest 5.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter PolymorphismsNCT04101227Change from baseline in the percentage of monthly heavy drinking days (PHDD)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: AD04 (ondansetron), Matching placebo · Device: Companion Diagnostic for Genetic Testing · Behavioral: Brief Psychological Counseling | Alcohol Use Disorder | 302 | 2022-02-18actual | 2024-04-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19